Genome Editing Market Size to grow by USD 7.23 billion between 2024-2028
According to a research report “ Genome Editing Market” by End-user (Pharmaceutical and biotechnology companies, Academic institutes and research laboratories, CRO) Delivery Mode (Ex-vivo, In-vivo) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 7.23 billion, at a CAGR of 15.88% during the forecast period. Genome editing technologies have experienced significant advancements in recent years, resulting in the emergence of more precise and efficient tools, such as CRISPR-Cas9, TALENs, and zinc finger nucleases (ZFNs). These innovative genome editing solutions enable researchers to target and modify specific genomic regions with unprecedented accuracy, expanding the scope of research and therapeutic applications. Beyond traditional gene knockout and insertion techniques, advancements in genome editing have introduced more sophisticated modifications, including base editing, prime editing, and epigenome editing. These techniques facilitate precise nucleotide changes, gene regulation, and epigenetic modifications, respectively, opening up new avenues for groundbreaking research and therapeutic developments. Furthermore, technological innovations have led to the development of high-throughput screening methods for genome editing, enabling researchers to expeditiously assess the impact of genetic modifications on cellular phenotypes..
Browse market data tables, figures, and in-depth TOC on “Genome Editing Market” by End-user (Pharmaceutical and biotechnology companies, Academic institutes and research laboratories, CRO) Delivery Mode (Ex-vivo, In-vivo) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample
By End-user, the Pharmaceutical and biotechnology companies segment is projected to dominate the market size in 2024
Genome editing is a revolutionary technology that empowers researchers to execute precise modifications on specific genes, enabling a deeper understanding of their functions in disease biology and drug response. By generating knock-out or knock-in mutations in target genes, scientists can investigate gene function, signaling pathways, and mechanisms of drug resistance, thereby uncovering essential insights into disease mechanisms and potential therapeutic targets. Pharmaceutical companies leverage these genome-edited cell lines and animal models to screen prospective drug candidates, validate drug targets, and evaluate drug efficacy in preclinical studies, ultimately contributing to the discovery and development of novel therapeutics for various diseases.
By Delivery Mode, Ex-vivo segment is expected to hold the largest market size for the year 2024
In the realm of genome editing, ex-vivo applications are gaining significant traction for therapeutic purposes, particularly in the treatment of genetic disorders, cancer, and infectious diseases. The increasing demand for ex-vivo genome editing therapies stems from their ability to target specific genetic mutations, correct disease-causing genes, or augment the therapeutic efficacy of cell-based treatments. This technology empowers the customization of cellular therapies and personalized medicine approaches by modifying patient-derived cells ex vivo. By tailoring treatments based on individual patients' unique genetic makeup, disease profile, and treatment response, ex-vivo genome editing is a critical component of precision medicine solutions. Furthermore, its role extends to the development of advanced cell-based therapies, such as stem cell therapies, CAR-T cell therapies, and gene therapies.
North America is forecasted to hold the largest market size by region in 2024
In North America, the biopharmaceutical and biotechnology industry is characterized by a robust ecosystem of pharmaceutical companies, biotech startups, contract research organizations (CROs), and academic research institutions. These entities are harnessing the power of genome editing technologies for various applications, including drug discovery, target validation, preclinical research, and therapeutic development. The region's burgeoning focus on personalized medicine and precision therapeutics is further fueling the demand for advanced genome editing tools, services, and expertise. By enabling the precise modification of disease-associated genes, genome editing technologies pave the way for the creation of customized treatments based on individual patients' genetic profiles. This increasing need for genome editing-based therapies and diagnostics is propelling market expansion in North America.
The Genome Editing Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:
.
For insights on company offerings- Request a sample report!
Research Analysis Overview
The Genome Editing Market is experiencing rapid growth due to the increasing demand for gene therapy and gene-editing technologies in the healthcare industry. These advanced technologies, including CRISPR-Cas9, TALENs, and ZFNs, have revolutionized molecular biology by enabling precise modification of DNA strands. One of the significant applications of genome editing is in the field of medicine, where it holds promise for treating genetic abnormalities such as sickle cell disease, hemophilia, cystic fibrosis (CF), breast cancer, multiple myeloma, and tumors. For instance, white button mushrooms have been engineered using gene-editing tools to produce a protein that can inhibit the growth of breast cancer cells. Clinical trials are underway to evaluate the efficacy of genome editing in treating various diseases, including cancer, AIDS, and Parkinson’s disease. Pro-code and SMR are two emerging genome editing tools that offer improved specificity and efficiency. Genome editing holds the potential to modify a single gene in an organism, providing a cure for genetic disorders and offering new hope for patients. However, ethical concerns surrounding genome editing and its potential impact on the environment remain a challenge for the industry. Regulatory frameworks, such as those established by the World Health Organization and the National Institutes of Health, are essential to ensure the safe and ethical use of genome editing technologies.
Market Research Overview
The genome editing market is a rapidly growing sector at the intersection of agriculture, biotechnology, and human health. Agriculturists and botanists are utilizing gene-editing technologies like CRISPR-Cas9 to develop GM seeds for crops such as canola, sugar beets, cotton, soybean, and corn. These modifications aim to enhance resistance to pests, improve nutritional value, and increase yield. In the realm of human health, genome editing is revolutionizing the development of large-molecule medicines for various diseases. For instance, researchers are targeting enzymes like polyphenol oxidase (PPO) in white button mushrooms to combat breast cancer. In the clinical trial pipeline, companies like Beam Therapeutics and Arcturus Therapeutics are pioneering prime editing and base editing for gene therapy in diseases such as stomach cancer, liver cancer, lung cancer, multiple myeloma, hemophilia, cystic fibrosis (CF), and genetic disorders like spinal muscular atrophy, peripheral artery disease, hearing loss, and Parkinson’s disease. The genome editing market encompasses gene delivery, drug discovery, cell line engineering, and in-vivo segment applications. It is a dynamic field that continues to evolve, with ongoing research and development in gene editing services, genetic manipulation, and therapeutics for a wide range of genetic abnormalities and diseases.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
